T1	Participants 351 399	patients with non-small-cell lung cancer (NSCLC)
T2	Participants 1291 1384	147 patients were randomized (median age: 60Â±8 years, PS 0/1/2: 44/83/20 patients; males: 78%
T3	Participants 1427 1524	18 of 73 patients achieving PFS15 in arm ED at the end of stage 2 and 17 of 74 patients in arm D.
